A federal judge in Sacramento, Calif., late yesterday declined to stop California Medicaid’s transfer of managed care drug coverage to Medicaid fee for service that took effect on Jan. 1. Health centers enrolled in the 340B drug pricing program pledged
…
A federal circuit court on Tuesday halted drug manufacturer Lilly and the federal government’s appeals of a district judge’s late October ruling in Lilly’s 340B contract pharmacy lawsuit, on technical grounds. It’s the second time the case has run into
…
The judge in AstraZeneca’s 340B contract pharmacy lawsuit yesterday ordered both sides to file a joint status report by no later than Friday—a sign, lawyers say, that his decision in the case is still in progress.
U.S. District Judge Leonard
…
The U.S. Health Resources and Services Administration (HRSA), the agency that runs the 340B drug pricing program, has a permanent leader again for the first time in almost a year.
Carole Johnson started in her position as HRSA administrator on
…
Federally qualified health clinics in California have no right to sue to stop a major state Medicaid drug reimbursement change that began on Jan. 1., the state Department of Health Care Services (DHCS) argued in a legal brief filed Wednesday.
…
Drug manufacturers AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them until all 340B-related federal court litigation is finished and until after the government finalizes its forthcoming new 340B ADR regulation.
…
The federal government told a judge in late December its appeal of her joint ruling in Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits justifies her pausing drug industry vendor Kalderos’ 340B contract pharmacy suit.
Kalderos told the judge
…
The Biden administration is rescinding an unimplemented Trump-era regulation that would have pegged Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers provide in similar countries.
The U.S. Centers for Medicare &
…
In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:
California health centers asked a federal district judge yesterday to stop a major state Medicaid drug reimbursement change due to begin tomorrow. They say the change would strip away all their 340B drug discount savings, devastating safety-net health care
…*Sign up for news summaries and alerts from 340B Report